Tags : JASMINE

Amgen and Allergan Report Results of ABP 798 (biosimilar, rituximab)

Tuba Khan August 23, 2019

Shots: The JASMINE study involves assessing of ABP 798 vs its reference product, Rituximab at a dose of 375 mg/m2 (IV, qw) for 4wks. followed by dosing at weeks 12 […]readmore

Tags : JASMINE

Amgen and Allergan Report Results of ABP 798 (biosimilar, rituximab)

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : JASMINE

﻿Amgen and Allergan Report Results of ABP 798 (biosimilar, rituximab)

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Amgen and Allergan Report Results of ABP 798 (biosimilar, rituximab)